# IP21-002, New Vaccine Surveillance Network

> **NIH ALLCDC U01** · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2024 · $1,234,285

## Abstract

SUMMARY (For Components A, B, and C). Acute gastroenteritis (AGE) and acute respiratory illness (ARI)
are leading causes of childhood disease, accounting for a large proportion of hospitalizations, Emergency
Department (ED) visits, and outpatient visits annually in the US. These illnesses are caused by diverse
pathogens, including influenza, respiratory syncytial virus, human metapneumovirus, parainfluenza viruses,
rhinovirus, enterovirus (EV), coronavirus including SARS-CoV-2, adenovirus, rotavirus, norovirus, astrovirus,
and sapovirus. Moreover, some of these viruses are associated with other emerging childhood syndromes,
including acute flaccid myelitis (AFM) associated with EV, and multisystem inflammatory syndrome in children
(MIS-C) associated with SARS-CoV-2. Thus, viral AGE and ARI are of major public health importance, and
result in serious long-term consequences for some children. There are few or no effective antivirals for these
viruses and vaccination is the most promising intervention. Our goals are to conduct active, prospective
population-based surveillance for AGE and ARI; to define the burden of vaccine-preventable diseases;
describe the clinical features, natural history, and population dynamics; and establish vaccine effectiveness
(VE) of licensed and impending vaccines and monitor VE over time. The New Vaccine Surveillance Network
(NVSN) will facilitate these goals. We propose four Specific Aims:
Aim 1: to conduct prospective active surveillance for AGE due to norovirus, rotavirus, and other
enteric viruses among children seeking healthcare in ED, inpatient, and outpatient settings.
(Component A, Mandatory Component 1; Optional Component B)
Aim 2: to conduct prospective active surveillance for ARI due to respiratory viruses in these settings.
(Component A, Mandatory Component 1; Optional Component B)
Aim 3: to conduct prospective active surveillance for AFM syndrome in these settings. (Component A,
Mandatory Component 2)
Aim 4: to conduct prospective active surveillance for MIS-C. (Optional Component C)
The Pittsburgh site has extensive experience with pediatric clinical research, including as a top enrolling NVSN
site in the current NVSN cycle. UPMC Children’s Hospital of Pittsburgh (CHP) has a catchment area of >5.5
million people and admits >95% of hospitalized children in the surrounding county of >1.2 million. Thus, the
environment is excellent for population-based research. The experienced investigative team includes experts
from pediatric infectious diseases, critical care, rheumatology, and cardiology. The data and samples collected
in this project will facilitate the capacity to calculate VE for multiple licensed and pending vaccines. The results
of this project will inform best practices for diagnosis and treatment, guide vaccine recommendations, and
determine public health interventions to prevent viral illness-related medical visits among children.

## Key facts

- **NIH application ID:** 11046458
- **Project number:** 5U01IP001152-04
- **Recipient organization:** UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- **Principal Investigator:** Marian G Michaels
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** ALLCDC
- **Fiscal year:** 2024
- **Award amount:** $1,234,285
- **Award type:** 5
- **Project period:** 2021-09-01 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11046458

## Citation

> US National Institutes of Health, RePORTER application 11046458, IP21-002, New Vaccine Surveillance Network (5U01IP001152-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/11046458. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*